BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 26980295)

  • 1. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over.
    Santoro N; Labopin M; Ciceri F; Van Lint MT; Nasso D; Blaise D; Arcese W; Tischer J; Bruno B; Ehninger G; Koc Y; Santarone S; Huang XJ; Savani BN; Mohty M; Ruggeri A; Nagler A
    Cancer; 2019 May; 125(9):1499-1506. PubMed ID: 30620383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
    Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
    Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Poiré X; Labopin M; Cornelissen JJ; Volin L; Richard Espiga C; Veelken JH; Milpied N; Cahn JY; Yacoub-Agha I; van Imhoff GW; Michallet M; Michaux L; Nagler A; Mohty M
    Am J Hematol; 2015 Aug; 90(8):719-24. PubMed ID: 26010466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.
    Eom KS; Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Lee S
    Am J Hematol; 2013 Aug; 88(8):634-41. PubMed ID: 23620000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
    Pagliardini T; Castagna L; Harbi S; Porta MD; Rey J; Fürst S; Bramanti S; Saillard C; Legrand F; Maisano V; Faucher C; Granata A; Hospital MA; Lining W; Weiller PJ; Calmels B; Charbonnier A; Lemarie C; Chabannon C; Vey N; Mokart D; Blaise D; Devillier R
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1803-1809. PubMed ID: 31128325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
    Rashidi A; Hamadani M; Zhang MJ; Wang HL; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolaños-Meade J; Byrne M; Cahn JY; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz MA; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee JW; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
    Blood Adv; 2019 Jun; 3(12):1826-1836. PubMed ID: 31201170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
    Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
    Buchholz S; Dammann E; Stadler M; Krauter J; Beutel G; Trummer A; Eder M; Ganser A
    Eur J Haematol; 2012 Jan; 88(1):52-60. PubMed ID: 21883483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.